(19)
(11) EP 2 981 258 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.11.2020 Bulletin 2020/46

(45) Mention of the grant of the patent:
12.08.2020 Bulletin 2020/33

(21) Application number: 14778339.3

(22) Date of filing: 03.04.2014
(51) International Patent Classification (IPC): 
A61K 31/341(2006.01)
A61K 47/02(2006.01)
A61K 9/08(2006.01)
A61P 9/12(2006.01)
 A61K 9/00(2006.01)
A61K 47/18(2017.01)
A61K 31/635(2006.01)
A61P 9/04(2006.01)
(86) International application number:
PCT/US2014/032800
(87) International publication number:
WO 2014/165660 (09.10.2014 Gazette 2014/41)

(54)

PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE

PHARMAZEUTISCHE FORMULIERUNGEN ZUR SUBKUTANEN VERABREICHUNG VON FUROSEMID

FORMULATIONS PHARMACEUTIQUES POUR L'ADMINISTRATION SOUS-CUTANÉE DE FUROSÉMIDE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.04.2013 US 201361808962 P

(43) Date of publication of application:
10.02.2016 Bulletin 2016/06

(60) Divisional application:
20189271.8

(73) Proprietor: scPharmaceuticals Inc.
Burlington, MA 01803 (US)

(72) Inventors:
  • MICHAELS, Scott, A.
    Boston, Massachusetts 02116 (US)
  • MUNTENDAM, Pieter
    Boston, Massachusetts 02116 (US)
  • LARSEN, Glenn, R.
    Boston, Massachusetts 02116 (US)

(74) Representative: Harrison IP Limited 
3 Ebor House Millfield Lane
Nether Poppleton, York YO26 6QY
Nether Poppleton, York YO26 6QY (GB)


(56) References cited: : 
EP-A1- 0 801 950
WO-A1-92/21769
US-A- 4 698 361
US-A1- 2008 076 828
US-B2- 8 372 809
 EP-B1- 1 078 636
US-A- 4 663 348
US-A- 5 814 623
US-A1- 2012 077 829
   
  • DEVARAKONDA ET AL: "Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 345, no. 1-2, 13 November 2007 (2007-11-13), pages 142-153, XP022342771, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.05.039
  • GHANEKAR A G ET AL: "STABILITY OF FUROSEMIDE IN AQUEOUS SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 6, 1978, pages 808-811, XP002760968, ISSN: 0022-3549
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).